Tiziana Life Sciences (TLSA) Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers
Tiziana Life Sciences plc (NASDAQ:TLSA and AIM: TILS), a clinical stage biotechnology company focused on developing targeted drugs for cancer and inflammatory diseases, is pleased to announce (further to the announcement made on 1 May 2019) that the U.S. Food and Drug Administration (FDA) has allowed the initiation of a Phase I clinical trial in healthy volunteers using a novel oral enteric-coated capsule formulation of Foralumab, a fully human monoclonal antibody (mAb), in collaboration with the Brigham and Women’s Hospital (BWH), Harvard Medical School, Boston, MA.
Are Biotech Stocks Setting The Stage For Another Bull Trend?
Biotech stocks and the biotech sector have proven to be one of the fastest-growing sectors over the last decade. According to most experts, it is expected to continue in the same vein in the foreseeable future. What could be in store?
Over 330 Mass Shootings!
There have been more mass shootings this year in the United States than there have been days in the year. This is becoming a huge issue that is costing precious lives and could see billions of dollars spent to fix this situation. One company has a technology product that could disrupt this multi-billion-dollar industry for the better.